Trial Information
Inclusion Criteria:
- histologically confirmed squamous NSCLC
- Previously treated with one or two lines of chemotherapy
- FGFR amplification (FISH > 5 copies of genes)
- 20 years or older
- ECOG PS 0-2
Exclusion Criteria:
- active infection
- uncontrolled brain metastasis
- unstable angina or MI
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
response rate
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Myung-Ju Ahn
Investigator Role:
Principal Investigator
Investigator Affiliation:
Samsung Medical Center
Authority:
Korea: Food and Drug Administration
Study ID:
2012-09-070-002
NCT ID:
NCT01861197
Start Date:
March 2013
Completion Date:
Related Keywords:
- Squamous NSCLC
- Efficacy
- Dovitinib
- Squamous NSCLC
- Carcinoma, Non-Small-Cell Lung